BackFate Therapeutics Overview
Fate Therapeutics Inc

Fate Therapeutics Target Price

Where could FATE trade next? Consensus target price: $5.6.

Get informed when a big investor buys or sells

+ Follow

Share Price

$2.44

Average Target Price

$5.63130.5% upside

4 analysts in the last 4 months

High: $8 | Low: $3.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-14Piper Sandler$8227.9% upsideOpen
2026-08-14Wells Fargo$3.543.4% upsideOpen
2026-06-08H.C. WainwrightDebjit Chattopadhyay$7186.9% upsideOpen
2026-05-19Jefferies$463.9% upsideOpen
2025-03-06Stifel Nicolaus$323% upsideOpen
2024-11-13BMO CapitalEtzer Darout$5104.9% upsideOpen
2024-08-14Stifel NicolausBenjamin Burnett$5104.9% upsideOpen
2024-06-17Piper SandlerEdward Tenthoff$6145.9% upsideOpen
2024-05-16H.C. WainwrightDebjit Chattopadhyay$5104.9% upsideOpen
2024-05-10Piper SandlerEdward Tenthoff$463.9% upsideOpen
2024-05-10BMO CapitalEtzer Darout$6145.9% upsideOpen
2024-05-10Canaccord GenuityBill Maughan$9268.9% upsideOpen
2023-01-09Goldman Sachs$463.9% upsideOpen
2023-01-06Morgan Stanley$8227.9% upsideOpen
2023-01-06Piper Sandler$12391.8% upsideOpen
2023-01-06BMO Capital$7186.9% upsideOpen
2023-01-05Truist FinancialRobyn Karnauskas$7186.9% upsideOpen
2022-12-15Goldman SachsAndrea Tan$10309.8% upsideOpen
2022-12-13Truist Financial$461785.2% upsideOpen
2021-12-13OppenheimerMatthew Biegler$1355432.8% upsideOpen
2021-11-08CitigroupYigal Nochomovitz$873465.6% upsideOpen
2021-11-05Roth CapitalAnthony Butler$602359% upsideOpen
2021-10-25JefferiesMichael Yee$1455842.6% upsideOpen
2021-08-20Piper SandlerEdward Tenthoff$1134531.1% upsideOpen

Fate Therapeutics (FATE) FAQ

Fate Therapeutics's target price stands at $5.6. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $5.6 for FATE implies 130.5% upside versus today's price ($2.44). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Fate Therapeutics's target price evolved across reporting periods, while the comparison chart places FATE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Fate Therapeutics's reading of $5.6 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.